摘要
目的探讨重组人血管内皮抑素(YH-16)辅助化疗治疗中晚期非小细胞肺癌(NSCLC)的临床疗效。方法将84例晚期NSCLC患者随机分为两组,对照组42例采用长春瑞滨(NVB)+顺铂(DDP)方案(NP方案)化疗,观察组42例采用YH-16联合NP方案化疗。2个周期后对两组近期疗效、临床获益、毒副反应进行评价。结果观察组的客观缓解率(ORR)、疾病控制率(DCR)及临床获益率均显著高于对照组(P<0.05),组内不同病理类型的ORR、DCR及临床获益率比较,差异无统计学意义(P>0.05),但TNM分期Ⅲ期的DCR显著高于Ⅳ期(P<0.05);观察组的中位OS显著长于对照组(P<0.05),组内不同病理类型的中位PFS比较差异无统计学意义(P>0.05),但腺癌的OS显著长于非腺癌(P<0.05),且Ⅲ期的PFS、OS显著长于Ⅳ期(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 YH-16联合化疗对不同病理类型中晚期NSCLC疗效确切,可延长生存周期并提高临床获益率,但疗效受TNM分期影响。
Objective To investigate the clinical efficacy of Rh-endostatin （YH-16） adjuvant chemotherapy in treatment of advanced non-small cell lung cancer （NSCLC）. Methods Totally 84 patients with advanced NSCLC were randomly divided into two groups. The 42 patients in control group received navelbine （NVB） plus cisplatin （DDP） chemotherapy （NP regimen）, while the other 42 patients in observa- tion group received target therapy of YH-16 combined with NP chemotherapy. The short-term efficacy, clinical benefit and toxicity were evaluated and compared after two cycles of treatment. Results The objective response rate （ORR）, disease control rate （DCR） and overall clinical benefit rate in the observation group were significantly higher than in the control group （P 〈 0.05）. There was no significant difference in ORR, DCR and clinical benefit rate between patients with different pathological types in the observation group （P〉0.05）, but the DCR of TNF stage III patients Was significantly higher than that of stage IV patients （P〈0.05）. The overall survival （OS） in observation group was significantly longer than in the control group （P 〈 0.05）. There was no statistical difference in PFS between patients with different pathologi- cal types within group （P〉0.05）. But the OS in adenocarcinoma subgroup was significantly longer than in non-adenocarcinoma subgroup （P〈O.05）, and PFS and OS in stage III subgroup was significantly longer than that in stage IV subgroup （P〈0.05）. There was no statistically significant difference in the incidence of toxicity between the two groups （P〉0.05）. Conclusion YH-16 combined with chemotherapy had exact effect on advanced NSCLC. This regimen could improve the clinical benefit rate and prolong survival time of NSCLC patients, but the effect was affected by TNM staging.
出处
《肿瘤药学》
CAS
2017年第2期189-194,共6页
Anti-Tumor Pharmacy
基金
四川省科技厅科技计划项目(2015JY0171)
关键词
非小细胞肺癌
重组人血管内皮抑素
长春瑞滨
顺铂
化疗
Non-small cell lung cancer
Recombinant human endostatin
Navelbine
Cisplatin
Chemotherapy
